CMV-specific immune reconstitution and outcome of CMV reactivation/disease in 25 patients who received CMV-specific T-cell therapy
Patient no. . | Cell therapy, day after transplantation . | CMV specific CD4+ reconstitution, day after cell therapy . | CMV-specific CD8+ reconstitution, day after cell therapy . | pp65 antigenemia after cell therapy* . | CMV disease (onset after transplantation, wk) . | Outcome (time after diagnosis, wk) . |
---|---|---|---|---|---|---|
1 | 16 | 21 | 21 | — | — | — |
2 | 23 | 21 | 21 | — | — | — |
3 | 14 | 21 | 21 | — | — | — |
4 | 21 | 21 | 21 | — | — | — |
5 | 13 | 21 | 21 | 10 | IP/CNS (2) | Resolution (3) |
6 | 32 | 21 | 21 | — | — | — |
7 | 37 | 21 | 21 | 7 ± 6 | CNS (12) | Death (4) |
8 | 16 | 21 | 21 | 13 ± 7 | Enteritis (15) | Death (2) |
9 | 37 | 21 | 21 | — | — | — |
10 | 26 | 21 | 21 | — | — | — |
11 | 15 | 21 | 21 | — | — | — |
12 | 22 | 21 | 21 | — | — | — |
13 | 21 | 21 | 21 | — | IP (3) | Resolution (4) |
14 | 21 | 21 | 21 | 4 ± 1 | — | — |
15 | 17 | 21 | 21 | — | — | — |
16 | 21 | 21 | 21 | 10 | — | — |
17 | 33 | 21 | 21 | — | — | — |
18 | 26 | 21 | 21 | — | — | — |
19 | 16 | 21 | 21 | 7 ± 3 | — | — |
20 | 28 | 21 | 21 | — | CNS (5) | Resolution (5) |
21 | 17 | 21 | 21 | — | — | — |
22 | 37 | 21 | 21 | 10 | — | — |
23 | 27 | 21 | 21 | — | — | — |
24 | 28 | 21 | 21 | — | — | — |
25 | 21 | 21 | 21 | — | — | — |
Patient no. . | Cell therapy, day after transplantation . | CMV specific CD4+ reconstitution, day after cell therapy . | CMV-specific CD8+ reconstitution, day after cell therapy . | pp65 antigenemia after cell therapy* . | CMV disease (onset after transplantation, wk) . | Outcome (time after diagnosis, wk) . |
---|---|---|---|---|---|---|
1 | 16 | 21 | 21 | — | — | — |
2 | 23 | 21 | 21 | — | — | — |
3 | 14 | 21 | 21 | — | — | — |
4 | 21 | 21 | 21 | — | — | — |
5 | 13 | 21 | 21 | 10 | IP/CNS (2) | Resolution (3) |
6 | 32 | 21 | 21 | — | — | — |
7 | 37 | 21 | 21 | 7 ± 6 | CNS (12) | Death (4) |
8 | 16 | 21 | 21 | 13 ± 7 | Enteritis (15) | Death (2) |
9 | 37 | 21 | 21 | — | — | — |
10 | 26 | 21 | 21 | — | — | — |
11 | 15 | 21 | 21 | — | — | — |
12 | 22 | 21 | 21 | — | — | — |
13 | 21 | 21 | 21 | — | IP (3) | Resolution (4) |
14 | 21 | 21 | 21 | 4 ± 1 | — | — |
15 | 17 | 21 | 21 | — | — | — |
16 | 21 | 21 | 21 | 10 | — | — |
17 | 33 | 21 | 21 | — | — | — |
18 | 26 | 21 | 21 | — | — | — |
19 | 16 | 21 | 21 | 7 ± 3 | — | — |
20 | 28 | 21 | 21 | — | CNS (5) | Resolution (5) |
21 | 17 | 21 | 21 | — | — | — |
22 | 37 | 21 | 21 | 10 | — | — |
23 | 27 | 21 | 21 | — | — | — |
24 | 28 | 21 | 21 | — | — | — |
25 | 21 | 21 | 21 | — | — | — |
— indicates no manifestations of CMV disease and negative antigenemia; IP, interstitial pneumonia; CNS, brain lesion.
Positive antigenemias (no. of positive cells/200 000 cells) detected weekly from 3 to 12 weeks after T-cell therapy. Single number indicates 1 episode of reactivation. Two numbers indicate 2 episodes of reactivation. Mean ± SD indicates 3 or more episodes of reactivation